Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07384052 · ClinicalTrials.gov registry record · Phase 1

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

A Phase 1 study of Spinal Cord Injury, sponsored by HealthPartners Institute.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT07384052 is a Phase 1 study of Spinal Cord Injury that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 12 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07384052, a Phase 1 study of Spinal Cord Injury, is actively recruiting participants, sponsored by HealthPartners Institute.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future. This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.

Conditions Studied

Spinal Cord Injury

Interventions

  • DRUG Regular Insulin
  • OTHER 0.9 % Normal Saline

Study Locations (1)

Minnesota

  • HealthPartners Neuroscience Center - Saint Paul

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-02-20
Est. Completion 2026-09
Phase Phase 1

Sponsor

HealthPartners Institute

146 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07384052

The ClinicalTrials.gov registry entry for NCT07384052 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower). The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Regular Insulin is the first listed.

NCT07384052 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07384052 about?

NCT07384052 is a clinical study titled "Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury". The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many pati...

What is the current status of trial NCT07384052?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02-20. Estimated completion is 2026-09.

What conditions does trial NCT07384052 study?

This clinical trial studies the following conditions: Spinal Cord Injury.

What interventions are being tested in trial NCT07384052?

The interventions under investigation include: Regular Insulin (DRUG), 0.9 % Normal Saline (OTHER).

Who is sponsoring clinical trial NCT07384052?

This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07384052 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Cord Injury

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.